Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

YMAB holding history

Y-mAbs Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

YMAB overviewAll 13F holders of YMABFull Q2 2026 holdings

Shares (Q3 2025)
0
Sold out in Q3 2025
Value
$0
% of portfolio
0.0%
Quarters held
18
Since Q1 2021
Holdings of YMAB by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q3 20250$00.0%−292,567−100.0%Sold outHolders
Q2 2025292,567$1.32M<0.1%−207,594−41.5%ReducedHolders
Q1 2025500,161$2.22M<0.1%+179,354+55.9%AddedHolders
Q4 2024320,807$2.51M<0.1%+72,085+29.0%AddedHolders
Q3 2024248,722$3.27M<0.1%+45,582+22.4%AddedHolders
Q2 2024203,140$2.45M<0.1%+15,043+8.0%AddedHolders
Q1 2024188,097$3.06M<0.1%−57,048−23.3%ReducedHolders
Q4 2023245,145$1.67M<0.1%+137,271+127.3%AddedHolders
Q3 2023107,874$587.9K<0.1%−22,748−17.4%ReducedHolders
Q2 2023130,622$886.9K<0.1%−119,827−47.8%ReducedHolders
Q1 2023250,449$1.25M<0.1%−43,514−14.8%ReducedHolders
Q4 2022293,963$1.43M<0.1%+38,471+15.1%AddedHolders
Q3 2022255,492$3.68M<0.1%−118,664−31.7%ReducedHolders
Q2 2022374,156$5.66M<0.1%−167,405−30.9%ReducedHolders
Q1 2022541,561$6.43M<0.1%+251,177+86.5%AddedHolders
Q4 2021290,384$4.71M<0.1%+206,378+245.7%AddedHolders
Q3 202184,006$2.40M<0.1%−8,160−8.9%ReducedHolders
Q2 202192,166$3.11M<0.1%−122,270−57.0%ReducedHolders
Q1 2021214,436$6.48M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.